Clinical study of radiotherapy for nasopharyngeal carcinoma

Takashi Toba, Y. Shioyama, S. Nomoto, S. Ohga, T. Yoshitake, K. Ohnishi, K. Atsumi, H. Terashima, H. Honda, K. Nakamura

研究成果: ジャーナルへの寄稿記事

抄録

This study was a retrospective analysis of 65 patients with histologically confirmed nasopharyngeal carcinoma, who were treated at Kyushu University Hospital from 1992 to 2005. Radiotherapy consisted of once daily 1.5-2.0 Gy fractions 5 times per week to a total of 60-81 Gy. Chemotherapy was combined with radiotherapy in 61 patients. Forty-five patients received concurrent chemoradiotherapy with daily 5-FU (250 mg/body/day) or TS-1 (100mg/body/day) . Sixteen patients alternatingly received concurrent chemoradiotherapy with daily 5-FU or carboplatin (40 mg/body/day) and systemic chemotherapy consisting of cisplatin (80 mg/m2, day 1) and peplomycin (5mg/body/day, days 2-6) after 30Gy irradiation. The five-year cause-specific survival (CSS) rate was 68%. CSS significantly favored the patients without lymph node metastasis. Local recurrence was observed in 14 patients, all of whom received radiotherapy for more than 75 days. Although prolonged duration of radiotherapy caused by chemotherapy regimen or its toxicity seemed to reduce effectiveness of radiation, chemoradiotherapy for patients with nasopharyngeal carcinoma might contribute to improving their survival.

元の言語英語
ページ(範囲)317-322
ページ数6
ジャーナルJapanese Journal of Clinical Radiology
53
発行部数2
出版物ステータス出版済み - 3 7 2008

Fingerprint

Radiotherapy
Chemoradiotherapy
Drug Therapy
Fluorouracil
Peplomycin
Survival
Carboplatin
Clinical Studies
Nasopharyngeal carcinoma
Cisplatin
Survival Rate
Lymph Nodes
Radiation
Neoplasm Metastasis
Recurrence

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

これを引用

Toba, T., Shioyama, Y., Nomoto, S., Ohga, S., Yoshitake, T., Ohnishi, K., ... Nakamura, K. (2008). Clinical study of radiotherapy for nasopharyngeal carcinoma. Japanese Journal of Clinical Radiology, 53(2), 317-322.

Clinical study of radiotherapy for nasopharyngeal carcinoma. / Toba, Takashi; Shioyama, Y.; Nomoto, S.; Ohga, S.; Yoshitake, T.; Ohnishi, K.; Atsumi, K.; Terashima, H.; Honda, H.; Nakamura, K.

:: Japanese Journal of Clinical Radiology, 巻 53, 番号 2, 07.03.2008, p. 317-322.

研究成果: ジャーナルへの寄稿記事

Toba, T, Shioyama, Y, Nomoto, S, Ohga, S, Yoshitake, T, Ohnishi, K, Atsumi, K, Terashima, H, Honda, H & Nakamura, K 2008, 'Clinical study of radiotherapy for nasopharyngeal carcinoma', Japanese Journal of Clinical Radiology, 巻. 53, 番号 2, pp. 317-322.
Toba, Takashi ; Shioyama, Y. ; Nomoto, S. ; Ohga, S. ; Yoshitake, T. ; Ohnishi, K. ; Atsumi, K. ; Terashima, H. ; Honda, H. ; Nakamura, K. / Clinical study of radiotherapy for nasopharyngeal carcinoma. :: Japanese Journal of Clinical Radiology. 2008 ; 巻 53, 番号 2. pp. 317-322.
@article{f53246a501ad43d4a2d683c6af54a32b,
title = "Clinical study of radiotherapy for nasopharyngeal carcinoma",
abstract = "This study was a retrospective analysis of 65 patients with histologically confirmed nasopharyngeal carcinoma, who were treated at Kyushu University Hospital from 1992 to 2005. Radiotherapy consisted of once daily 1.5-2.0 Gy fractions 5 times per week to a total of 60-81 Gy. Chemotherapy was combined with radiotherapy in 61 patients. Forty-five patients received concurrent chemoradiotherapy with daily 5-FU (250 mg/body/day) or TS-1 (100mg/body/day) . Sixteen patients alternatingly received concurrent chemoradiotherapy with daily 5-FU or carboplatin (40 mg/body/day) and systemic chemotherapy consisting of cisplatin (80 mg/m2, day 1) and peplomycin (5mg/body/day, days 2-6) after 30Gy irradiation. The five-year cause-specific survival (CSS) rate was 68{\%}. CSS significantly favored the patients without lymph node metastasis. Local recurrence was observed in 14 patients, all of whom received radiotherapy for more than 75 days. Although prolonged duration of radiotherapy caused by chemotherapy regimen or its toxicity seemed to reduce effectiveness of radiation, chemoradiotherapy for patients with nasopharyngeal carcinoma might contribute to improving their survival.",
author = "Takashi Toba and Y. Shioyama and S. Nomoto and S. Ohga and T. Yoshitake and K. Ohnishi and K. Atsumi and H. Terashima and H. Honda and K. Nakamura",
year = "2008",
month = "3",
day = "7",
language = "English",
volume = "53",
pages = "317--322",
journal = "Japanese Journal of Clinical Radiology",
issn = "0009-9252",
publisher = "Kanehara Shuppan Co. Ltd",
number = "2",

}

TY - JOUR

T1 - Clinical study of radiotherapy for nasopharyngeal carcinoma

AU - Toba, Takashi

AU - Shioyama, Y.

AU - Nomoto, S.

AU - Ohga, S.

AU - Yoshitake, T.

AU - Ohnishi, K.

AU - Atsumi, K.

AU - Terashima, H.

AU - Honda, H.

AU - Nakamura, K.

PY - 2008/3/7

Y1 - 2008/3/7

N2 - This study was a retrospective analysis of 65 patients with histologically confirmed nasopharyngeal carcinoma, who were treated at Kyushu University Hospital from 1992 to 2005. Radiotherapy consisted of once daily 1.5-2.0 Gy fractions 5 times per week to a total of 60-81 Gy. Chemotherapy was combined with radiotherapy in 61 patients. Forty-five patients received concurrent chemoradiotherapy with daily 5-FU (250 mg/body/day) or TS-1 (100mg/body/day) . Sixteen patients alternatingly received concurrent chemoradiotherapy with daily 5-FU or carboplatin (40 mg/body/day) and systemic chemotherapy consisting of cisplatin (80 mg/m2, day 1) and peplomycin (5mg/body/day, days 2-6) after 30Gy irradiation. The five-year cause-specific survival (CSS) rate was 68%. CSS significantly favored the patients without lymph node metastasis. Local recurrence was observed in 14 patients, all of whom received radiotherapy for more than 75 days. Although prolonged duration of radiotherapy caused by chemotherapy regimen or its toxicity seemed to reduce effectiveness of radiation, chemoradiotherapy for patients with nasopharyngeal carcinoma might contribute to improving their survival.

AB - This study was a retrospective analysis of 65 patients with histologically confirmed nasopharyngeal carcinoma, who were treated at Kyushu University Hospital from 1992 to 2005. Radiotherapy consisted of once daily 1.5-2.0 Gy fractions 5 times per week to a total of 60-81 Gy. Chemotherapy was combined with radiotherapy in 61 patients. Forty-five patients received concurrent chemoradiotherapy with daily 5-FU (250 mg/body/day) or TS-1 (100mg/body/day) . Sixteen patients alternatingly received concurrent chemoradiotherapy with daily 5-FU or carboplatin (40 mg/body/day) and systemic chemotherapy consisting of cisplatin (80 mg/m2, day 1) and peplomycin (5mg/body/day, days 2-6) after 30Gy irradiation. The five-year cause-specific survival (CSS) rate was 68%. CSS significantly favored the patients without lymph node metastasis. Local recurrence was observed in 14 patients, all of whom received radiotherapy for more than 75 days. Although prolonged duration of radiotherapy caused by chemotherapy regimen or its toxicity seemed to reduce effectiveness of radiation, chemoradiotherapy for patients with nasopharyngeal carcinoma might contribute to improving their survival.

UR - http://www.scopus.com/inward/record.url?scp=40149108042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40149108042&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:40149108042

VL - 53

SP - 317

EP - 322

JO - Japanese Journal of Clinical Radiology

JF - Japanese Journal of Clinical Radiology

SN - 0009-9252

IS - 2

ER -